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Abstract 
In rheumatoid arthritis (RA), nocturnal release of pro-inflammatory cytokines is not adequately 
counteracted by endogenous glucocorticoid, and is associated with symptoms of morning stiffness 
and pain.  Taking exogenous glucocorticoid during the night reduces morning stiffness significantly 
more than treatment at the conventional time in the morning, though waking to take tablets is 
unacceptable for patients. Modified-release prednisone tablets have beenwas developed to allow 
administration at bedtime for programmed delivery of glucocorticoid during the night. Single centre 
crossover studies were conducted, each in ≥24 healthy subjects, to compare the pharmacokinetics of 
a single 5 mg oral dose of modified-release prednisone and conventional prednisone, and the effect 
of food on bioavailability. There was no substantial difference in pharmacokinetic parameters of the 
formulations apart from the programmed delay in release of glucocorticoid from the modified-
release tablets (Cmax 97%, AUC0-∞ 101%, 90% confidence intervals within the requisite range for 
bioequivalence). Administration after a full or light meal did not affect pharmacokinetic 
characteristics, but bioavailability was reduced under fasted conditions. Pharmacokinetic evaluation 
in nine patients with RA confirmed that modified-release prednisone tablets taken at bedtime 
(around 22:00 h) with or after an evening meal result in programmed release of glucocorticoid 4–6 
hours after intake.  
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The circadian pattern in symptoms is a well-known feature of rheumatoid arthritis (RA).1, 2  Typically, 
patients experience joint stiffness and pain in the morning; it lasts for more than an hour in 24–49% 
of patients.1, 2  Stiffness may be present even in patients in remission or with minimal disease 
activity.1  Morning symptoms may impair functional abilities, with adverse impact on wellbeing.3  
Furthermore, working ability may be impaired, with severity of morning stiffness a key factor in early 
retirement from work in the 3 years after RA diagnosis.3, 4  Yet despite the widespread occurrence of 
morning stiffness and its impact on patients, treatment is often unsatisfactory.5 
 
There is increasing awareness of the underlying pathophysiology of morning symptoms in RA.6, 7  
Nocturnal levels of the pro-inflammatory cytokine, interleukin-6 (IL-6) correlate with morning 
stiffness.8, 9  In patients with RA, the normal nocturnal increase in endogenous cortisol appears to be 
insufficient to counteract increased nocturnal levels of IL-6.6, 7, 10  Exogenous glucocorticoid may be 
given to supplement endogenous glucocorticoid.7, 11  Prednisone and its therapeutically-equivalent 
metabolite, prednisolone, are oral glucocorticoids commonly used in RA.11, 12  Both glucocorticoids 
have a short half-life of approximately 2 hours and are usually administered in the morning.13  
However, efficacy with respect to morning stiffness and pain is improved if treatment is given during 
the night,14 before the peak in IL-6, though it is unacceptable in the long term for patients to have to 
wake to take medication.   
 
To facilitate delivery at the optimal time, in accordance with circadian rhythms, a modified-release 
formulation of prednisone has been developed.15  These tablets, consisting of an active drug core 
inside an inert coat, are designed for administration at bed time (approximately 22:00 h).  After a lag 
period during which it absorbs fluid, the coat opens to allow drug release at approximately 02:00 h.  
Clinical studies have demonstrated a reduction in the duration of morning stiffness following 
administration of modified-release prednisone compared with placebo and the same dose of 
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conventional prednisone administered in the morning.8, 9, 15-17  Studies were undertaken in healthy 
subjects to compare the pharmacokinetic characteristics of modified-release prednisone with 
conventional prednisone and to assess the impact of food on bioavailability.  Another study, 
conducted to investigate the influence of modified-release prednisone on circadian IL-6 plasma 
levels using 24-h blood sampling in nine patients with RA, also included analysis of plasma 
prednisone levels.  Results reporting the clinical findings and IL-6 levels have been reported 
previously.8, 9  The findings on prednisone plasma levels are reported here to provide additional 
insight into the pharmacokinetic characteristics of modified-release prednisone  was conducted to 
confirm the pharmacokinetic characteristics in patients with RA taking modified-release prednisone 
under practical conditions.   
 
MATERIALS AND METHODS 
Studies conducted in healthy subjects were each carried out at a single centre (the key study, KS1, 
and supportive study, SS1: Antwerp, Belgium; supportive studies SS2 and SS4: Berlin, Germany; 
supportive study SS3: Miami, USA).  The study in patients (P1) was also conducted at a single centre 
(Bristol, UK).  Written informed consent was obtained from all subjects.  All study designs received 
ethical approval.  Studies were conducted in accordance with the Declaration of Helsinki and with 
local applicable laws and guidelines. 
 
Subjects 
All healthy subjects were non-smokers aged over 18 years and were of general good health as 
evidenced by medical and drug history, body mass index, physical examination, 12-lead 
electrocardiograms, vital signs and safety laboratory variables.  No concomitant drug intake was 
allowed.  In the study of nine patients with RA, stable medication for the management of the disease 
was permitted. 
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Formulation 
Modified-release prednisone tablets (Lodotra®), as formulated for commercial use (i.e. in vitro lag 
period of 3.5–4.5 h, mean 3.9 h), were used in all studies at a dose of 5 mg.  In addition, 
developmental formulations with in vitro lag period of 3.0–3.5 h, 4.0–5.0 h and 4.5–5.5 h (mean in 
vitro lag time of 3.2 h, 4.4 h and 4.9 h, respectively) were evaluated in supportive study SS4.  
Conventional prednisone tablets 5 mg (Decortin®, Merck KGaA, Darmstadt, Germany) were used in 
the key study, KS1, and supportive studies SS1 and SS2.   
 
Study designs 
All studies in healthy subjects were single-dose, open-label, randomised, crossover design.  In all 
studies, the allocation of subjects to treatment sequence was randomised.  The washout period 
between treatment arms was at least 3 days, with follow-up 3–9 days after the last treatment.  
Treatments were swallowed whole with 240 mL of room temperature tap water with subjects in a 
standing position at administration and for the following 10 mins.   
 
The key study (KS1) was a three-arm crossover study designed to reflect the relevant clinical 
comparison, namely conventional prednisone taken in the fasting state with evening administration 
of modified-release prednisone taken after either a light or a full meal.  The sequence for allocation 
to each of the three treatment periods was according to a randomisation list (SAS Plan procedure).  
The primary objective of this study was to compare the bioavailability of prednisone and 
prednisolone from the reference formulation (conventional prednisone) and the test formulation 
(modified-release prednisone) after a light or full meal.  The secondary objective was to assess the 
effect of food on the pharmacokinetic profile and bioavailability of modified-release prednisone. 
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allowed direct comparison of tablets formulated for commercial use after a full meal and a light 
meal, and direct comparison with conventional prednisone taken in the fasting state.   
 
The timing of the dose and prior food intake varied in the supportive studies (SS1 – SS4), as 
summarised in Table 1, allowing direct comparisons to be made within the studies, and indirect 
comparisons between studies.   
 
In the study conducted in patients with RA (P1), modified-release prednisone tablets 5 mg were 
taken once daily for 14 days.  Patients were asked to take the treatment in accordance with the 
summary of product characteristics i.e. at bedtime (approximately 22:00 h), with or after an evening 
meal; if 2–3 hours had passed since the meal, the treatment was to be taken with a light snack.  
Patients were instructed not to take modified-release prednisone tablets in the fasting state. 
 
Sample collection and analysis 
In all studies, blood samples were collected before and at intervals throughout the 24-h following 
drug administration to measure plasma levels of prednisone and the active metabolite, 
prednisolone.  In-dwelling cannulas were used to facilitate collection and minimise trauma.  Samples 
(5 mL) of blood from healthy subjects (studies KS1 and SS1 – SS4) were collected into tubes 
containing lithium heparin, centrifuged (4°C, 2500 rpm, 15 mins).  Samples of blood from patients 
with RA (study P1) were collected into chilled ethylenediaminetetraacetic acid and centrifuged 
(room temperature, 5750 rpm, 7 mins).  In all studies, plasma was transferred to two polypropylene 
tubes for storage at –20°C.  Frozen samples were analysed using a liquid chromatography/tandem 
mass spectroscopy method with limit of quantification (LOQ) of 0.25 ng/mL for prednisone and 1 
ng/mL for prednisolone. 
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Pharmacokinetic analysis 
Absorption profiles were determined from the prednisone serum concentrations using Thermo 
Scientific Kinetica software (version 4.4.1), using the Wagner-Nelson modified template.  
Pharmacokinetic parameters were derived from plasma concentrations of prednisone and 
prednisolone, calculated according to standard methods using WinNonlin Professional Edition 
(version 3.0) with all deviations from theoretical sampling times taken into account in the analysis.  
Pharmacokinetic parameters (except tmax: time to maximum plasma concentration and tlag: last time 
point with concentration below LOQ) were log-transformed and analysed by analysis of variance 
(ANOVA) with subject, sequence, period and treatment as factors.  The mean square error of the 
ANOVA derived from Cmax (maximum observed plasma concentration) and AUC0–∞ (area under the 
plasma concentration versus time curve from time 0 extrapolated to infinity) were used to calculate 
the 90% confidence intervals for the difference between treatments in each study, on the log scale.  
Estimates of ratios between treatments were obtained by back-transformation.  The time 
parameters, tmax and tlag were analysed using non-parametric methods. 
 
RESULTS 
Subjects 
A total of 135 healthy subjects (116 men, 86%) and nine patients with RA (three men, 33%) 
participated in the studies.  Demographic information for the healthy subjects included in sStudies 
KS1 and SS1 – SS4 each included 24 or more subjects (range 24–28) of normal body mass; studies 
KS1, SS1 and SS4 were restricted to male subjects only.  The mean age of subjects in each study 
ranged from 32 years (SS1) to 51 years (SS3); the overall age range of individuals included in the 
studies was from 18 years to 60 years. is summarised in Table 2.  In the study conducted with 
patients (P1), the mean age of the nine subjects (three male and six females) was 65 years (range 
51–79 years).  Mean duration of RA in the patient study (P1) was 17.2 years; two patients had 
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recently diagnosed disease (duration ≤2 years) with and all others having had disease duration ≥16 
years.  Five patients were seropositive and all patients had evidence of erosions.  Two patients 
smoked, three were ex-smokers and four patients were non-smokers.  Seven patients were on 
concomitant therapy with disease-modifying antirheumatic drugs (DMARDs) and seven with non-
steroidal anti-inflammatory drugs (NSAIDs). 
 
Pharmacokinetic comparison between modified-release prednisone and conventional prednisone 
In the key study allowing direct comparison (KS1), there was no visible difference in the prednisone 
absorption profile (Figure 1) and plasma concentration profile with conventional and modified-
release tablets (Figure 2), apart from the programmed delay in release of glucocorticoid.  Compared 
with conventional prednisone, modified-release prednisone taken after a light meal had a lag time of 
3.5 h (90%CI: 3.3–3.8 h) with peak plasma concentration after at 46.0 h (90% CI: 3.5–4.5 h) (Table 
32).  As with conventional prednisone, >80% of drug was released from modified-release prednisone 
tablets within 2 h of opening.  The rate and extent of absorption were bioequivalent, with Cmax of 
97% and AUC0–∞ of 101% for prednisone from modified-release tablets relative to conventional 
tablets, and 90% confidence intervals for both key parameters within the requisite range (80–125%).  
Similar findings were observed for plasma levels of the active metabolite, prednisolone (Table 32).   
 
The key study, KS1, compared evening administration of modified-release prednisone (20:00 h) 
directly with night time administration of conventional prednisone (02:00 h).  However, 
conventional prednisone is usually taken in the morning.  A supportive study (SS1) allowed direct 
comparison of morning (08:00 h) and night time (02:00 h) administration of conventional 
prednisone.  In this study, Cmax and AUC0–∞ values were about 20% lower with morning dosing than 
night time dosing (geometric mean Cmax 16.817 vs 20.621 ng/mL; AUC0–∞ 93.994 vs 108 h.ng/mL).  
Another supportive study (SS2) allowed direct comparison of modified-release prednisone taken as 
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licensed (at 22:00 h after a light meal) and conventional prednisone taken as usual (08:00 h after 
breakfast) and confirmed that the pharmacokinetic characteristics of the two preparations are 
essentially the same (AUC0–∞: 90%, Cmax: 99%) apart from a lag time of approx 4 h.  The difference 
between treatments was 4.5 h for tlag and 3.5 h for tmax.   
 
Impact of food on pharmacokinetics of modified-release prednisone 
In a direct comparison, the absorption of prednisone from the modified-release tablets was the 
same in healthy subjects taking the medication immediately after a full evening meal and a few 
hours after a light meal (key study KS1, data not shown).  Indirect comparison with supportive study 
SS3 suggested that a high-fat meal did not appear to enhance absorption further (data not shown).  
 
The impact of food on plasma levels of prednisone are shown in Figure 3a (direct comparison of 
dosing in the evening after a main meal and a few hours after a light meal, using data from the key 
study, KS1) and Figure 3b (direct comparison of the fed and fasted state from supportive study SS3).  
There was no statistically significant effect of dosing after a main meal or a few hours after a light 
meal, with Cmax in the fed state 108% (90% CI: 96–122%) relative to the light meal and relative 
bioavailability of 112% (90% CI: 100–125%) for AUC0–∞.  However, there was a 3- to 4-fold reduction 
in bioavailability under overnight fasted conditions compared with the fed state after a full 
breakfast.   
 
Consistency between studies and subjects 
Despite the variations in dosing time and dietary state prior to administration of the modified-
release tablets, indirect comparisons between studies suggested that there was broad consistency in 
the key pharmacokinetic parameters.  The absorption profile of modified-release prednisone was 
determined in studies KS1, SS2, SS3 and SS4.  In all studies, the profiles were consistent with the 
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expected results from the in vitro lag period (3.5–4.5 h).  In supportive study SS4, which included 
developmental formulations as well as the commercial formulation of modified-release prednisone, 
in vivo lag times were approximately 1 h longer than the in vitro lag times and closely correlated 
(correlation coefficients of 0.96–0.98).  The plasma concentrations of prednisone and derived 
pharmacokinetic parameters were comparable in the four studies of healthy subjects taking 
modified-release prednisone after a full meal (Table 42). 
 
Three of the 27 subjects (11%) included in the pharmacokinetic analysis of supportive study SS2 
showed plasma concentration of prednisone/prednisolone after administration of modified-release 
prednisone that were significantly below average.  Variability in data arising from these three 
subjects resulted in 90% CI for the difference in geometric means of Cmax and AUC0–∞ for the 
treatments being outside the range of 80–125% (modified-release prednisone relative to 
conventional prednisone, Cmax: 98.799%, 90% CI 78.879–123.7124%; AUC0–∞: 89.990%, 90% CI 
69.870–1165.8%).  However, reanalysis omitting these outliers extreme values resulted in 90% CI 
within the required range for equivalence.  Low absorption was also observed in eight of the 108 
doses taken (7%) in study SS4, which investigated tablets with different in vitro lag times.  These 
outliers extreme values  were distributed at random between subjects and treatment groups.  The 
variability in data meant that test formulations were not bioequivalent to the commercial 
formulation, using formal bioequivalence criteria.  However, there was consistency in Cmax and AUC0–
∞ when such outliers extreme values were excluded, indicating that the in vitro lag time in the 
selected range (3.0 – 5.0 h) did not affect bioavailability. 
 
Pharmacokinetics of modified-release prednisone in patients with RA 
Pharmacokinetic parameters in patients with RA (study P1) confirmed the findings with healthy 
subjects.  Six of the nine patients showed a steep rise in prednisone concentration after 4.75 h, 
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indicating that the modified-release prednisone tablet had opened by this time; the remaining three 
patients showed a rise in the blood sample an hour later, as shown in Figure 4. 
 
DISCUSSION 
The studies reported here, conducted in both healthy subjects and patients with RA, demonstrated 
that modified-release prednisone tablets give programmed delivery of glucocorticoid 4–6 hours after 
intake.  All other pharmacokinetic parameters (AUC0–∞, Cmax, absorption curves) are close to values 
for the same dose of a conventional immediate-release tablet formulation, thus meeting the formal 
definition of bioequivalence if the conventional preparation is taken 4–6 hours after the modified-
release formulation.  These special pharmacokinetic characteristics allow modified-release 
prednisone tablets to be taken at bed time (approximately 22:00 h) to deliver anti-inflammatory 
glucocorticoid in the early morning hours (approximately 02:00 h) at the optimal time to counteract 
the nocturnal rise in pro-inflammatory cytokines.     
 
There are some limitations in the studies reported here.  Each study was small in size and the 
different conditions and administration times make a direct comparison between studies difficult.  
Nevertheless, the studies consistently showed similarity with conventional prednisone (except for 
the programmed lag period) and little difference between administration after small or large meals.  
The study in patients (P1) enrolled only nine subjects for a study with the primary objective of 
assessing circadian IL-6 levels as the protocol requiring determination of pharmacokinetic 
parameters requires repeated measurements throughout a 24-h period so is onerous on patients 
and medical staff.  Nevertheless, the pharmacokinetic profile of prednisone obtained findings from 
this small clinical study were was consistent with results in healthy subjects.  Furthermore, modified-
release prednisone in these nine patients was shown to suppress the early morning rise in IL-6, 
enhance the nocturnal levels of endogenous cortisol and significantly reduce morning stiffness, pain 
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and inflammatory markers (p≤0.028).8, 9  The reported efficacy in clinical studies15-17 also confirms 
that the programmed delivery of glucocorticoid from modified-release prednisone tablets occurs in a 
satisfactory manner in patients with RA. 
 
In two supportive studies in healthy subjects, the occurrence of a small number of outliers extreme 
values was observed.  In study SS4, modified-release prednisone was evaluated in all treatment 
arms, with 7% of doses resulting in low absorption.  In the modified-release prednisone treatment 
arm of study SS2, three subjects (11%) showed low absorption.  Such reduced absorption may be 
due to variability in gastric emptying and rapid transit of the tablet through the gastrointestinal tract 
with release of the active drug from the tablet in an area of low absorption (e.g. the colon).  The 
findings from the clinical study suggests a greater variation in absorption rate for patients than 
healthy subjects, though these patients were older and varied considerably more than healthy 
subjects in age, smoking status and other characteristics.  Patients were advised to take the 
medication at approx 22:00 h, but as in clinical practice, there were no checks on adherence with 
instruction.  Despite the variability, the lag period for release of prednisone was still within the 
target range of 4–6 h.  It seems likely that any variability in pharmacokinetic characteristics would 
have little clinical relevance.  The intra-individual comparison in study SS4 indicated that low 
absorption profiles were distributed at random throughout treatment groups and subjects.  It thus 
appears unlikely that this variability has any relevance to the practical use of this modified-release 
formulation.  In the phase III clinical trial, the proportion of patients with no morning stiffness after 
9–12 months of treatment with modified-release prednisone increased from 0 to 17% and those 
with stiffness for less than an hour increased from 10% to 29%.17  Conversely, the proportion of 
patients with prolonged morning stiffness fell; at the end of the study, 10% of patients reported 
morning stiffness lasting more than 3 hours (down from 33%) and 26% reported stiffness of 1–3 
hours (down from 46%).  These findings suggest that the majority of patients responded to 
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treatment.  Furthermore, guidelines stress the importance of monitoring the patient’s response to 
treatment.18  Consequently, any variability within a patient that consistently results in unsatisfactory 
clinical response should be identified and treatment should be adjusted accordingly.   
 
The studies evaluated the impact of food on the pharmacokinetic parameters of modified-release 
prednisone.  Bioavailability was reduced in fasted subjects compared with those who had eaten a 
few hours before drug administration, but there was no substantial difference between a full or light 
meal.  Consequently, as advised in the summary of product characteristics, modified-release 
prednisone tablets should be taken after a light snack if it is more than 2–3 hours since last meal, 
and should not be taken in the fasted state. 
 
Modified-release prednisone differs markedly in mechanism of release from enteric-coated 
prednisolone.  The release of drug from enteric-coated tablets is dependent on pH and location 
within the gastrointestinal tract, whereas the release of prednisone from modified-release tablets 
relies on the absorption of fluid into the inert coat, which is time-dependent but not pH-dependent.  
Food has been shown to interfere with both the absorption and the pharmacokinetics of 
prednisolone from enteric-coated tablets, resulting in considerable variability in plasma levels.19  In a 
study of healthy volunteers taking enteric-coated prednisolone after a meal, in some subjects 
absorption of prednisolone was delayed for 12 h and remained at a measurable level for 24 h, while 
in others a normal pattern (as observed after fasting) was observed.  Furthermore, unlike modified-
release prednisone tablets, enteric-coated tablets do not address the need for programmed delivery 
of glucocorticoid to match the circadian rhythm of endogenous cortisol release. 
 
There is growing realisation that circadian rhythms play a role in a number of conditions, prompting 
the use of timed therapeutic interventions (chronotherapy).  In essential hypertension, taking an 
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angiotensin-converting enzyme (ACE) inhibitor at bedtime significantly increased the proportion of 
patients with controlled ambulatory blood pressure compared with the same dose taken in the 
conventional manner, in the morning.20  Furthermore, bed time dosing significantly reduced blood 
pressure during the night, which has been shown to be a more relevant marker of cardiovascular risk 
than mean diurnal blood pressure.  In hypercholesterolaemia, statins taken at night appear to be 
more effective than the same treatment taken during the day.21  Such approaches have the potential 
to increase efficacy of existing therapies, by optimising the administration regimen.  In RA, this may 
allow prolongation of treatment with relatively inexpensive therapies before much more costly 
interventions (e.g. biological therapies) are required.22   
 
In conclusion, the studies reported here demonstrate that the pharmacokinetics of modified-release 
prednisone are essentially unchanged from conventional prednisone, apart from a programmed 4–6 
hour delay in glucocorticoid release.  This important feature allows medication to be taken at bed 
time resulting in improved clinical effects during the night, when required.  Drug absorption and 
pharmacokinetics are similar irrespective of administration after a full or light meal.  Findings in 
healthy subjects have been confirmed in patients with RA. 
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Table 1. Summary of treatment times and prior food intake in the key study (KS1), supportive studies in healthy subjects (SS1 – SS4) and a study of 
patients with RA (P1)studies 
Studies N Treatment arms 
Prednisone 5 mg Time of administration Fed state Prior food intake 
Key study in healthy subjects 
KS1 27 Modified-release 20:00 h Semi-fed Light meal at 17:30 
  Modified-release 20:00 h Fed Dinner at 19:30 h 
  Conventional 02:00 h Fasted No food for >10 h 
Supportive studies in healthy subjects 
SS1 28 Conventional 08:00 h Fasted No food for >10 h 
  Conventional 02:00 h Fasted No food for >10 h 
SS2 28 Modified-release 22:00 h Fed Dinner at 21:00 h 
  Conventional 08:00 h Fed Breakfast at 07:30 h 
SS3 24 Modified-release 08:00 h Fasted No food for >10 h 
  Modified-release 08:00 h Fed High-fat breakfast at 07:30 h 
SS4 28 Modified-release 22:00 h Fed Dinner at 21:00 h 
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  Modified-release* 22:00 h Fed Dinner at 21:00 h 
Study in patients with RA 
P1 9 Modified-release 22:00 h (approx.) Fed/semi-fed Dinner/light meal within 2–3 h 
*Three formulations assessed with different in vitro lag times (3.0–3.5 h, 4.0–5.0 h and 4.5–5.5 h) 
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Table 2. Demographic characteristics of subjects and patients included in the studies 
  
 Studies in healthy subjects Patients with RA 
 KS1 SS1 SS2 SS3 SS4 P1 
No. of subjects, n 27 28 28 24 28 9 
No. of males, n (%) 27 (100%) 28 (100%) 21 (75%) 12 (50%) 28 (100%) 3 (33%) 
Age  
  Mean, years (±SD) 
  Range, years 
 
34.8 (9.7) 
20–48  
 
31.5 (9.1) 
18–46  
 
34.0 (7.5) 
20–45  
 
51.4 (7.1) 
32–60  
 
34.7 (7.0) 
21–45  
 
64.6 (9.5) 
51–79  
Body weight 
  Mean, kg (±SD) 
  Range, kg 
 
75.0 (9.5) 
58.2–92.3  
 
75.0 (9.8) 
58.9–98.3  
 
75.2 (11.1) 
56.3–97.4  
 
73.2 (8.8) 
57.8–98.0  
 
78.8 (8.8) 
64.1–98.5  
 
74.6 (16.9) 
48.4–103.4  
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Table 32. Pharmacokinetic parameters for prednisone and prednisolone in blood after a single oral dose of conventional prednisone 5 mg or modified-
release prednisone 5 mg following a light meal (key study KS1) and for prednisone after modified-release prednisone 5 mg following a full meal (studies 
KS1 and SS2–4) 
Pharmacokinetic 
parameters 
Prednisone Prednisolone Prednisone after full meal 
Conventional Modified-release 
(after light meal) 
Comparison modified-release vs 
conventional 
Conventional Modified-release 
(after light meal) 
Comparison modified-release vs 
conventional 
KS1 SS2 SS3 SS4 
Point 
estimate 
90% CI* P** Point 
estimate 
90% CI* P** 
Cmax, ng.mL 
tmax, h 
tlag, h 
AUC0–∞, h.ng/mL 
20.721 (19.0–
22.523) 
2.0 (1.0–4.0) 
0.0 (0.0–0.5) 
109 (101–118) 
20.2 (18.519–
21.922) 
6.0 (4.5–10.0) 
3.5 (2.0–5.5) 
110 (101–119) 
97% 
4.0 h 
3.5 h 
101% 
86–110% 
3.5–4.5 h 
3.3–3.8 h 
90–113% 
0.54 
<0.0001 
<0.0001 
0.15 
135 (124–147) 
1.0 (0.5–3.0) 
0.0 (0.0–0.5) 
626 (583–672) 
113 (104–123) 
5.0 (4.0–9.0) 
3.5 (2.0–5.5) 
574 (535–617) 
84% 
4.3 h 
3.5 h 
92% 
74–94% 
4.0–4.8 h 
3.3–3.8 h 
83–101% 
0.036 
<0.0001 
<0.0001 
0.076 
22 
6.5 
4.0 
126 
18 
7.0 
4.5 
109 
19 
7.0 
4.5 
103 
17 
8.0 
5.0 
103 
Values given are least-squares geometric means (90% CI) except for tmax and tlag, which are given as median (range)  
*90% CI for the ratio of the true averages derived for pharmacokinetic parameters (derived from ANOVA for continuous parameters and derived from 
Wilcoxon signed rank test for tmax and tlag) 
**P value probability associated with the hypothesis of no significant difference between formulations (ANOVA except for tmax and tlag: Friedman test) 
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Table 4. Summary of pharmacokinetic parameters for prednisone following administration of a single dose of modified-release prednisone 5 mg after a 
full meal in healthy subjects 
Pharmacokinetic 
parameters 
KS1 SS2 SS3 SS4 
Cmax, ng.mL 
tmax, h 
tlag, h 
AUC0–∞, h.ng/mL 
t½, h 
22.2 (3.7) 
6.50 (1.11) 
3.87 (0.39) 
126.0 (24.3) 
2.43 (0.29) 
17.8 (6.1) 
7.00 (0.94) 
4.61 (0.66) 
109 (39.4) 
2.55 (0.47) 
19.1 (3.2) 
6.90 (1.14) 
4.46 (0.62) 
103.0 (18.9) 
2.54 (0.45) 
16.6 (7.2) 
7.90 (1.89) 
5.08 (1.26) 
103.2 (43.5) 
2.72 (0.47) 
Values given are means (SD)  
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Figure 1. Absorption of prednisone after a single oral dose of conventional prednisone 5 mg and 
modified-release prednisone 5 mg (key study KS1) 
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Figure 2. Mean concentration of prednisone in plasma after a single oral dose of conventional 
prednisone 5 mg and modified-release prednisone 5 mg (key study KS1) 
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Figure 3. Impact of food on mean concentration of prednisone in plasma after a single oral dose of 
modified-release prednisone 5 mg  
 
a) Full meal vs light meal (key study KS1)  
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b) Full meal vs fasted (supportive study SS3)  
 
 
Paper revised following submission to J Clin Pharmacol 16Nov11 
 
 
Figure 4. Concentration of prednisone in plasma from nine patients with RA after 2 weeks of 
therapy with modified-release prednisone 5 mg/day (study P1) 
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